Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Reversible BTK poster at ASH meeting

RNS Number : 0243R
Redx Pharma plc
06 December 2016
 

6 December 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

 

Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016

 

Redx, the drug development company, is pleased to announce that it has presented the pre-clinical profile of its reversible Bruton's tyrosine kinase (BTK) inhibitor RXC005 at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California, United States, on 5 December 2016.

 

Redx's development candidate RXC005 is a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and cysteine-481 (C481) mutated BTK. First generation BTK inhibitors, such as ibrutinib and acalabrutinib, specifically target C481 within BTK and mutations at this site interfere with covalent drug binding. Several mutations have been reported and linked to cases of resistance that have emerged in patients with chronic lymphocytic leukaemia (CLL) progression following treatment with ibrutinib. Redx's reversible BTK inhibitor RXC005 aims to overcome this resistance mechanism by targeting both wild type and C481-mutated BTK.

 

The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.

 

Dr Neil Murray, CEO of Redx, said:

 

"We're delighted to have presented the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the ASH 2016 meeting in San Diego.

 

"RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017."

 

The ASH Poster for RXC005 (poster #4399) is available on the Investor section of the Company's website: www.redxpharma.com/investors.html

 

 

 

For further information, please contact:

 

Redx Pharma Plc

 

Neil Murray, Chief Executive

T: +44 1625 469 900

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies/ Michael Reynolds

 

 

 

 

 

About Redx Pharma Plc

Company website: Redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUVRURNSAURUA



Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use